The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
TWST.COM Logo
  • Home
  • Experts
  • Reports
  • Products
  • News
  • About Us
  • Series
    • General Investing
    • Financial Services
    • Consumer
    • Industry & Services
    • Natural Resources
    • Healthcare
    • Technology
  • Contact Us

Immunomedics, Inc.

Related Interviews

Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
September 30, 2020
Singh, Hartaj

Finding Innovation and Value Opportunities in Health Care Small Caps
August 16, 2017
Arens, Matt

Oncology and Orphan Drugs Retain Pricing Power
August 14, 2013

Bradford Zakes - Imarx Therapeutics, Inc. (imrx)
September 24, 2007

Stephen Chubb - Matritech Inc (mzt)
November 14, 2005

Richard Otto - Corautus Genetics Inc (caq)
October 26, 2004

Stephen Seiler - Hybridon Inc (hybn)
June 02, 2003

Edward Wristen - First Health Group Corporation (fhcc)
November 01, 2002

Arthur Sands - Lexicon Genetics Inc (lexg)
June 02, 2002

Merchant Power Companies & Utilities: Thomas Hamlin - Wachovia Securities
October 29, 2001

Edward Voboril - Wilson Greatbatch Technologies Inc (gm)
October 12, 2001

Michael Potter - Big Lots, Inc. (bli)
June 07, 2001

Outlook For Electric Utilities: Samir Nangia -credit Lyonnais Securities Inc.
May 31, 2001

Richard Parry - Tom Johnson Investment Management
January 29, 2001

James Herbert - Neogen Corporation (neog)
May 29, 2000

James E. Tait - Vesta Insurance Group Inc (vta)
February 14, 2000

Cart

Latest News

The Robots from this Company Will Build You a New Spine
Lord Abbett Portfolio Manager Reveals the Process for Picking Winning Innovative Growth Stocks
Fundamental Analysis on Small Cap Stocks: Value Upside Returns

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

Subscribe now!

Sign Up For Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews

Interview with the CEO: Niagen Bioscience Inc. (NASDAQ:NAGE)

Robert Fried

Published March 02, 2026 in Biotechnology and Pharmaceuticals

Companies covered: NAGE

Buy ($25)

Interview with the CEO: Vaxart Inc. (OTCMKTS:VXRT)

Steven Lo

Published March 02, 2026 in Biotechnology and Pharmaceuticals

Companies covered: VXRT

Buy ($25)

Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB)

Frank Bedu-Addo

Published March 02, 2026 in Biotechnology and Pharmaceuticals

Companies covered: PDSB

Buy ($25)

Most Popular Reports

Biotechnology and Pharmaceuticals

Published March 02, 2026

Topics covered: Biotechnology and Pharmaceuticals

Buy ($175)

Medical Devices and Life Science Tools

Published February 23, 2026

Topics covered: Medical Devices and Life Science Tools

Buy ($175)

Investing Strategies: Micro, Small and Smid Cap

Published February 05, 2026

Topics covered: Micro, Small and Smid Cap

Buy ($175)

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
GE Aerospace (General Electric Company)
Walmart Inc.
IBM (International Business Machines Corp.)
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Niagen Bioscience Inc. (NASDAQ:NAGE)
Interview with the CEO: Vaxart Inc. (OTCMKTS:VXRT)
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Supply Constraints Translate Into Pricing Power for Eagle Materials
Share Price Pullback Creates Attractive Entry Point for Urban Outfitters
VSE Corp: A Play on Strong Aerospace Aftermarket Demand
ANALYST INTERVIEWS
Argenx Builds Momentum on Strong Execution and Expanding Indications
Omeros Tackles Lethal Transplant Risks with First-in-Class Therapy
Uptick in M&A Among Tailwinds Boosting Biotech Sector
Subscribe Today!
Since 1963
© The Wall Street Transcript 2016, 2026
Terms and Conditions
Privacy Policy
 
 
https://www.twst.com/wp-admin/admin-ajax.php
  • Join now for free!
  • Already a member?

or create an account with a social network.

Join with Facebook
Join with Twitter
Join with Google
Join now! | Forgot password?

or login using a social network


Log in with Facebook
Log in with Twitter
Log in with Google